Shares of Depomed (NASDAQ:DEPO) have received an average rating of “Hold” from the eleven research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $9.29.
DEPO has been the topic of a number of recent analyst reports. Roth Capital set a $10.00 price target on shares of Depomed and gave the company a “buy” rating in a report on Friday, March 2nd. Piper Jaffray reiterated a “hold” rating and set a $8.00 price target on shares of Depomed in a report on Thursday, March 1st. BidaskClub cut shares of Depomed from a “sell” rating to a “strong sell” rating in a report on Wednesday, February 7th. Mizuho reiterated a “buy” rating and set a $9.00 price target on shares of Depomed in a report on Friday, March 23rd. Finally, ValuEngine cut shares of Depomed from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd.
In related news, SVP Matthew M. Gosling sold 45,519 shares of the firm’s stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $6.58, for a total value of $299,515.02. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 2.59% of the company’s stock.
Shares of NASDAQ:DEPO traded down $0.26 during trading on Friday, reaching $6.58. 424,100 shares of the stock traded hands, compared to its average volume of 891,282. Depomed has a 52-week low of $4.31 and a 52-week high of $13.90. The company has a quick ratio of 0.70, a current ratio of 0.74 and a debt-to-equity ratio of 3.21. The stock has a market cap of $434.45, a price-to-earnings ratio of -5.22 and a beta of 1.19.
Depomed (NASDAQ:DEPO) last posted its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.15 EPS for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.05. Depomed had a negative net margin of 26.92% and a negative return on equity of 45.19%. The firm had revenue of $94.41 million for the quarter, compared to analysts’ expectations of $88.75 million. sell-side analysts anticipate that Depomed will post -1.03 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This article was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3339172/depomed-depo-receives-9-29-average-pt-from-brokerages.html.
Depomed Company Profile
Depomed, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.